• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Food & Drug Administration (FDA)

Diabetes double play: Medtronic launches MiniMed 670G, Dexcom wins FDA nod for Android G5 app

June 7, 2017 By Fink Densford

Medtronic, Dexcom

Medtronic (NYSE:MDT) and Dexcom (NSDQ:DXCM) today announced respective wins for their diabetes care tech, with Medtronic launching its hybrid closed loop MiniMed 670G in the US and Dexcom winning an FDA nod for a Google (NSDQ:GOOG) Android G5 Mobile application. Fridley, Minn.-based Medtronic’s MiniMed 670G is designed to automatically track and adjust blood sugar levels in patients […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: DexCom Inc., Medtronic

Magellan widens lead test recall

June 7, 2017 By Sarah Faulkner

Magellan Diagnostic's LeadCare

The FDA this week expanded its Class I recall of lead poisoning tests from Magellan Diagnostics to include 2 additional testing systems. The regulatory watchdog said it recalled Magellan’s LeadCare testing systems because they may underestimate blood lead levels and provide inaccurate results with venous blood samples. “Falsely lower test results may lead to improper patient […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Recalls Tagged With: magellandiagnostics, meridianbioscience

BD wins 510(k) for intestinal bacteria diagnostic

June 5, 2017 By Sarah Faulkner

Becton Dickinson

Becton Dickinson (NYSE:BDX) said today that it won 510(k) clearance from the FDA for its molecular test that detects harmful intestinal bacteria causing infectious diarrhea. With the approval of its BD Max extended enteric bacteria panel, the company said the majority of pathogens causing acute gastroenteritis can be detected on its automated BD Max molecular […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Becton Dickinson

AntriaBio seeks FDA nod for trial of once-weekly insulin

June 5, 2017 By Sarah Faulkner

AntriaBio

AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes. The first-in-human study is slated to evaluate the […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: antriabio

Medtech stories we missed this week: June 2, 2017

June 2, 2017 By Danielle Kirsh

From Implandata receiving CE Marking to Inolife eyeing up-listing, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Dextera seeks expanded indications for MicroCutter 5/80 stapler Dextera Surgical announced in a June 1 press release that it has filed a 510(k) with the FDA for its MicroCutter 5/80 stapler. The […]

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: c2 Therapeutics, Dextera Surgical, DreaMed Diabetes, EndoGastric Solutions Inc., Implandata, Inolife, medtech, MicroTransponder Inc.

Trump budget proposes $1B FDA user fee increase

June 2, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group The Trump Administration’s proposed 2018 federal budget would boost Food and Drug Administration user fees from medical device and drug registrants by more than $1 billion, in contrast to ongoing Congressional user fee negotiations that do not include such steep increases. Get the full story here at the Emergo Group’s […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, Emergo Group

Bayer wins FDA nod for connected MS auto-injector

May 31, 2017 By Sarah Faulkner

Bayer BetaConnect auto-injector

Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector. The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Regulatory/Compliance, Wall Street Beat Tagged With: Bayer AG

Novo Nordisk seeks to include cardiovascular data in Tresiba insulin label

May 30, 2017 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) said today that it submitted a supplemental application to the FDA, asking to include cardiovascular data on the label of its Tresiba insulin degludec. The Danish insulin-maker asked to include data specifically from the Devote trial, which evaluated the cardiovascular safety of Tresiba compared to insulin glargine in patients with Type II diabetes. The […]

Filed Under: Cardiovascular, Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

FDA deals setback to Sunovion for inhaled COPD therapy

May 30, 2017 By Sarah Faulkner

Sunovion Pharmaceuticals

The FDA issued a complete response letter to Sunovion Pharmaceuticals in regards to the new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The investigational eFlow closed-system nebulizer delivers a long-acting muscarinic antagonist bronchodilator, glycopyrrolate, to reduce airflow obstruction in COPD patients. The company said it plans to work with the FDA to determine […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory Tagged With: Sunovion Pharmaceuticals

FDA cybersecurity workshop offers long-term solutions for medical device sector

May 30, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group The US Food and Drug Administration’s latest workshop on medical device cybersecurity issues, held May 18 and 19, 2017, firmly established myriad challenges in mitigating this risk, and that no easy or quick fixes are yet available to help manufacturers and other stakeholders address these challenges. Get the full story […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, Emergo Group

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 77
  • Page 78
  • Page 79
  • Page 80
  • Page 81
  • Interim pages omitted …
  • Page 94
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS